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The Acute Effect of Piretanide upon Serum and Urinary Calcium in 
Normal Subjects 
Cristina Casco,* Patricia Fainstein Day,* and Carlos Mautalen, MD* 
We gave piretanide, a new diuretic, at two dose levels to six 
normal subjects. Sodium excretion increased six to 
eightfold in the first two hours, and diuresis was completed 
within four hours. There was a simultaneous increase in the 
excretion of calcium which exceeded the amount present 
In the mobilized extracellular fluid. The resulting deficit of 
calcium produced a small but significant fall in serum 
calcium corrected for protein. After diuresis ended, cal-
cium was retained but not sodium, when compared to 
basal values on the previous day. The fall in urinary cal-
cium and the failure to correct the sodium deficit may both 
have resulted from increased secretion of parathyroid hor-
mone (PTH), which increases calcium reabsorption and 
decreases sodium reabsorption. The role of PTH in the 
long-term effects of diuretics on sodium and calcium excre-
tion requires further study. 
l o ten t diuretics such as thiazides, furosemide, and eth-
acrynic acid have a marked effect on calcium metabolism. 
Thiazides produce a significant fall in urinary calcium 
excretion (1-3) and, in some circumstances, a rise in serum 
calcium (4-8); the mechanism of these effects has been 
extensively studied (9-12). Furosemide, on theother hand, 
induces a prompt rise in calcium excretion (13-15), which 
is blunted during prolonged administration (16). During 
furosemide treatment, serum calcium does not change in 
patients with initially normal levels (17). We report the 
acute effect of two different dose levels of piretanide (3-
Pyrrolidine-4-phenoxy-5-sulfamoybenozoic acid), a new, 
high-ceiling diuretic with a sulfonamide structure (18), on 
serum and urinary calcium and phosphate in normal men. 
Materials and Methods 
The age, sex, weight, and blood pressure of the six normal 
volunteers are shown in Table 1. The subjects were studied 
during three consecutive days: Day i was a control; on Day 
2, 3 mg of piretanide was given orally at 10 a.m.; on Day 3, 
6 mg of piretanide was given orally at 10 a.m. To assure an 
adequate urine volume, the volunteers drank 500 ml of 
water at 8 a.m., and 250 ml at 10 a.m., 12 noon, and 2 p.m. 
During the two days before the study and on the three test 
days, the subjects ate their usual home diets; but to avoid 
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large dietary changes in sodium or calcium intake, the 
following items were not allowed: milk and all dairy 
products except butter, and all foods with a high sodium 
content such as broth, crackers, and cold cuts. 
On each day, urine was collected during the following 
periods: 8-10 a.m., 10 a.m.-12 noon; 12-2 p.m., 2-4 p.m., 
and 4-8 a.m. on the next day. Blood samples were obtained 
each day at 9 a.m. and 1 p.m. Sodium, calcium, phosphate, 
and creatinine were measured on each sample of urine, 
and calcium, phosphate, creatinine and total protein were 
measured on each sample of serum, using previously pub-
lished methods (19). Serum calcium was corrected for 
protein according to the formula: Corrected Ca= measured 
Ca/(0.6 -I- total proteins/18.5). This formula assumes that 
the total calcium is 60% ultrafiltrable and that the protein-
bound fraction changes in proportion to total protein (4). 
TABLE I 
Age, Sex, Weight, Height and Blood Pressure of 
Six Normal Volunteers 
Basal Blood 
Patient Age Sex Weight (kg) Height (cm) pressure (m 
1 42 M 77.5 177 110/70 
2 23 F 66.4 167 120/80 
3 37 F 63.5 164 110/80 
4 20 M 61.1 180 110/70 
5 31 F 60.7 170 110/60 
6 22 F 47.7 152 115/70 
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TABLE II 
Effect of Oral Administration of Piretanide at 10 a.m. Upon Urinary Volume, Sodium, and Calcium Excretion* 
Postdiuretic 
Before Piretanide After Piretanide Diuretic Period Period Total 24 Hrs 
8-10 a.m. 10 a.m.-12 noon 12 noon-2 p.m. 2-4 p.m. 10 a.m.-2 p.m. 2 p.m.-8 a.m. 
Basal 279 + 51 344 ±69 266 ±58 177±29 610±97 973 ±101 1861 ±1561 
Piretanide 3mg 217±69 699 ±173= 317±102 171 ±50 1016±165 922 ±128 2155 ±342 
Piretanide 6mg 163±47 1001±150S 321 ±83 110±49 1322 ±1053 597 ±94 2083 ±141 
Basal 11 ±3 11 ±3 11 ±2 8±3 22±5 56±9 90±14 
Piretanide 3mg 7±2 57±18'' 32±13 11±2 89±153 52±11 149 ±221 
Piretanide 6mg 6±1 84±16s 25±8(D) 12±9 109±103 50±13 164±181 
Basal 13±3 10±1 10±1 9±2 20±1 93±19 126±20 
Piretanide 3mg 10±2 40±10'' 22±8 10±2 62±102 57±7^ 128±13 
Piretanide 6mg 10±2 55±9« 21 ±3" 6±2 76 ±6= 51 ±25 136±26 
' p < 0.05 compared to basal period 
^p <0.01 compared to basal period 
^p < 0.001 compared to basal period 
"p < 0.05 compared to 8-10 a.m. period 
'p < 0.01 compared to 8-10 a.m. period 
"p < 0.001 compared to 8-10 a.m. period 
* Results are average ± SEM. 
Results 
After both doses of piretanide had been given, the increases 
in sodium, water, and ca lc ium excret ion were rapid in 
onset and were comple ted in four hours (Table 11). As we l l 
as values for indiv idual periods, the Table also shows 
cumulat ive values f o r t he durat ion o f t h e diuresis (10 a.m.-2 
p.m) and for the remainder of the study per iod (2 a.m.-8 
a.m.). After diuresis subsided, there was no fall in sodium 
excret ion despite a persistent sod ium defici t , but there was 
a signif icant fall in ca l c ium excret ion compared to the 
contro l day (Table 11), so that total 24-hour urinary ca lc ium 
was not increased. The dif ferent effects of piretanide on 
sodium and ca lc ium are compared in Fig. 1. Fig. 2 shows 
the ind iv idual values for ca lc ium excret ion dur ing the 
postdiuret ic per iod (4 a.m.-8 a.m.). 
O n e subject w i t h a relatively high basal excret ion showed 
a decrease after 3 mg of piretanide but a return to basal 
levels w i t h the 6 mg dose. Meanwh i l e , all other subjects 
showed a signif icant d im inu t i on . 
No changes were observed in total serum ca lc ium after 
piretanide administrat ion (Table III). However , the serum 
protein level rose so that corrected serum ca lc ium was 
signif icantly lower a t the t ime of peak act ion o f t h e diuret ic . 
No changes were observed in the serum levels of phos-
phate. A l though the urinary excret ion of phosphate rose in 
some subjects, this effect was inconsistent and the mean 
changes in urinary phosphate excret ion, renal phosphate 
clearance, and renal tubular reabsorpt ion of phosphate 
were not signif icant. 
The administrat ion of piretanide d id not induce a signif i-
cant change in serum or urinary creat in ine levels, but the 
creat inine clearance dur ing the 10 a.m. -2 p.m. per iod was 
lower after the 6 mgdose (basal: 91 ± 7 m l / m ; piretanide 3 
mg:88 ± 9 m l / m ; piretanide 6 mg:81 ± 8; P<0 .005 as 
compared to basal per iod). 
Piretanide produced some decrease in body weight but no 
change in b lood pressure. Transient side effects consist ing 
main ly of headache, dizziness, and uneasiness were ob-
served w i t h the 6 mg dose. 
Discussion 
The urinary excret ion of ca lc ium depends on glomerular 
f i l t rat ion and subsequent tubular reabsorpt ion. Approx i -
mately 70% o f t h e f i l tered load is reabsorbed in the prox i -
mal convo lu ted tubule and 20% in the ascending l imb of 
Henle 's loop. At both sites the reabsorption of ca lc ium 
fo l lows closely the reabsorpt ion of sod ium. Finally, 6 to 9% 
o f t h e f i l tered ca l c ium is reabsorbed in the distal tubule and 
co l lec t ing duct by mechanisms independent o f sodium 
reabsorpt ion, but probably under hormonal cont ro l , espe-
cia l ly parathyroid hormone (PTH) secretion. Piretanide, a 
TABLE III 
Serum Calcium Levels 3 Hrs After Piretanide Administration 
Basal day Piretanide 3 mg Piretanide 6 mg 
Total serum calcium 9.4±0.2 
(mg/dl) 
Total proteins 
(g/dl) 
7.6±0.2 
9.4 ±0.2 
7.8±0.2 
Corrected serum 9.33±0.23 9.18±0.2* 
calcium (mg/dl) 
* p < 0.05 student's test for paired samples 
9.5±0.2 
8.0±0.1 
9.17±0.2r 
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new diuretic with structural similarities to bumetanide and 
furosemide, is a natriuretic agent that has an important 
inhibitory action on sodium and chloride transport in the 
ascending portion of the loop of Henle (20). 
In the present study we observed a prompt increase of 
sodium and calcium excretion but no changes in urinary 
phosphate after the oral administration of piretanide. Simi-
lar observations have been reported by Teredesai and 
Puschett (20), who studied urinary electrolyte excretion 
during the peak natriuretic period after the intravenous 
administration of piretanide. The increased excretion of 
calcium observed in the present study was most likely the 
result of decreased reabsorption of sodium or chloride, 
induced by the administration of piretanide. However, the 
calcium loss was disproportionate to the increment ob-
served in urinary sodium. 
The loss of 66 mEq (3 mg dose) and 87 mEq (6 mg dose) of 
sodium (Table IV) with an osmotically equivalent amount 
of water would reduce both plasma and extracellular fluid 
(ECF) volumes by 470 and 620 ml, respectively, assuming a 
serum sodium concentration of 140 mEq/1. These volumes 
of ECF would contain 27 and 35 mg of calcium, respec-
tively, assuming that ultrafiltrable calcium was 60% oftotal 
calcium. With both doses of piretanide, the observed in-
creases in calcium excretion were greater than could be 
accounted for by mobilization of ECF. The differences of 15 
mg and 21 mg represent deficits which, if evenly distributed 
over an ECF volume of 14 liters, would reduce the calcium 
concentration by 0.11 and 0.15 mg/dl, respectively. These 
predicted changes are very close to the decreases in cor-
rected serum calcium which we observed (Table IV). 
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Fig. 2 
Whatever the mechanism, the fall in corrected calcium, 
and presumably also in ionized calcium, would be ex-
pected to increase the secretion of PTH. This hormone 
increases the tubular reabsorption of calcium (21), so that 
increased PTH secretion is a likely explanation for the fall 
in calcium excretion which occured during the evening 
and night after piretanide had been administered. The 
acute administration of PTH also increases the urinary 
excretion of sodium (21), so that increased PTH secretion 
may be one reason for the failure of sodium excretion to 
drop after diuresis ends, as would be expected in response 
to a sodium deficit. After the 3 mg dose of piretanide, the 
deficit was still uncorrected when the 6 mg dose was given, 
so that its effect may have been slightly blunted. 
It is interesting to compare the response to piretanide with 
the response to mercurial diuretics. The latter produce an 
increase in calcium and sodium excretion in the same 
proportion as their ECF concentrations and no decline in 
corrected plasma calcium; but after diuresis subsides, there 
is substantial retention of both sodium and calcium (22). 
This suggests that there are two different mechanisms for 
increased calcium reabsorption and fall in calcium excre-
tion after an acute diuresis. If the loss of calcium is dis-
proportionate to the lossof sodium, there is a fall in ionized 
calcium and increased secretion of PTH. Conversely, ifthe 
loss of calcium is proportionate to the loss of sodium, there 
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T A B L E IV 
Relationship Between C h a n g e s in P lasma and Urinary Calcium after Piretanide 
Piretanide 3 mg 
-^66 Change in sod ium excret ion* (mEq) 
Change in ca lc ium excret ion (mg) observed* 
expected** 
d i f ference 
-1-42 
-1-27 
- H 5 
Change in ca lc ium concent ra t ion 
(mg/d l ) 
-0.15 
-0.11 
Piretanide 6 mg 
+ B7 
- f56 
+2^ 
- 0 . 1 6 
- 0 . 1 5 
observed 
expec ted** * 
'Changes in sodium and calcium excretion are differences between basal and experimental days from 10 a.m. to 2 p.m. 
** Calcium contained in the mobilized ECF, assuming that sodium concentration was 140 mEq/1 and that ultrafiltrable calcium was 60% oftotal calcium. 
*** Assuming that calcium lost in excess of amount contained in mobilized ECF is distributed in the remaining ECF volume of 14 liters. 
wil l be no change in ionized calcium or PTH secretion, but 
increased sodium reabsorption in response to volume 
contraction. 
In some respects, the action of piretanide resembles the 
action of furosemide. When given to patients with partial 
parathyroid insufficiency, this diuretic induced a significant 
drop in ionized calcium, an increase in PTH secretion (in 
spite of the partial surgical hypoparathyroidism), and mark-
edly augmented urinary calcium excretion (23). The failure 
to limit the increase in calcium excretion may have re-
sulted from a suboptimal PTH response to the fall in 
ionized calcium. In normal subjects, furosemide increases 
urinary calcium excretion significantly in the first eight 
hours (15), but then with continued administration, it re-
turns to base line levels (16). This is the expected result o fa 
return of sodium excretion to the pretreatment level, an 
adaptive response probably mediated by increased sodium 
reabsorption in the proximal tubule and loop of Henle, in 
response to volume contraction. Absence of a steady state 
change in sodium excretion is characteristic of all diuretics 
and is accompanied by a parallel lack of steady change in 
calcium excretion, with the exception of thiazide diuretics, 
which produce a sustained fall in urinary calcium. Further 
studies are needed to determine the relative importance of 
increased PTH secretion and sodium adaptation in modify-
ing the long-term effects of piretanide and other diuretics 
on the urinary excretion of calcium. 
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